

Learner Notification

**Society of Gynecologic Oncology
2025 Winter Meeting
January 30, 2025 – February 1, 2025
Whistler BC, Canada**

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation #4008163.

Professions in scope for this activity are listed below.

Physicians

Amedco LLC designates this live activity for a maximum of **12.50 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Amedco LLC designates this activity for a maximum of **12.50 ANCC contact hours**.

Pharmacists and Pharmacy Technicians

Amedco LLC designates this activity for a maximum of **12.50 knowledge-based CPE contact hours**.

- **ACPE Topic Code 01 – 10.00 CE – UAN: JA4008163-9999-25-004-L01-P**
- **ACPE Topic Code 99 – 2.50 CE – UAN: JA4008163-9999-25-005-L99-P**

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Objectives - After Attending This Program You Should Be Able To

1. Identify and discuss the latest updates in treatment and management of gynecologic cancers.
2. Review novel therapies and clinical trials and how they have the potential to change outcomes for patients with gynecologic cancers.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

| Last | First | Commercial Interest |
|------------|-----------|--|
| Alvarez | Secord | Clinical trial for the institution relationship with Roche/Genentech; Clinical trial for the institution relationship with Karyopharm; Clinical trial for the institution relationship with Immunogen; Clinical trial for the institution relationship with I-MAB Biopharma; Clinical trial for the institution relationship with GSK; author relationship with UpToDate; Clinical Trial for the institution relationship with Ellipses Pharma; Clinical Trial for the institution relationship with Eisai; Clinical Trial for the institution relationship with Clovis; Steering Committee for clinical trial relationship with Hoffman-LaRoche, CanariaBio; Clinical Trial for the institution relationship with Astra Zeneca; Advisory Board relationship with AbbVie/Immunogen; Institution relationship with Clovis; Institution relationship with Ellipses Pharma, Roche/Genentech, GSK, I-MAB Biopharma, Immu; Advisory Board relationship with AbbVie/Immunogen; Clinical Trial grant with institution relationship with Abbvie; Clinical Trial grant with institution relationship with Aravive; To institution relationship with Aravive; to Institution relationship with AbbVie; Part of financial planner managed account relationship with Johnson & Johnson; Part of financial planner managed account relationship with Amgen; Research grant for the institution relationship with Zentalis; Research grant for the institution relationship with VBL Therapeutics; Research grant for the institution relationship with Seagen Inc; Research grant for the institution relationship with OncoQuest/Canaria Bio; Research grant for the institution relationship with Mersana; to Institution relationship with AstraZeneca; Clinical trial for the institution relationship with Merck |
| Arend | Rebecca | Board Membership relationship with AstraZeneca Pharmaceuticals LP; Grant relationship with ImmunoGen, Inc.; Grant relationship with AbbVie; Grant relationship with Champions Oncology, Inc.; Consulting relationship with Merck Sharp and Dohme, LLC; Grant relationship with Exelixis Inc.; Grant relationship with Other-LifeNet; Grant relationship with Regeneron Pharmaceuticals, Inc.; Grant relationship with Other-Artera; Grant relationship with Faeth Therapeutics; Grant relationship with Other-LEAP Therapeutics |
| Backes | Floor | Consulting relationship with clovis; Grant relationship with tempus; Consulting relationship with Myriad; Consulting relationship with EMD Serono; Consulting relationship with Daiichi Sankyo; Consulting relationship with BioNTech; Grant relationship with immunogen; Consulting relationship with immunogen; Grant relationship with clovis; research support relationship with glaxosmithkline; research support relationship with astrazeneca; Grant relationship with merck; research support relationship with natera; Consulting relationship with glaxosmithkline; Consulting relationship with astra zeneca; Consulting relationship with eisai; Consulting relationship with merck |
| Baker | William | NA |
| Bashashati | Ali | NA |
| Berry | Laurel | NA |
| Binder | Pratibha | NA |
| Bixel | Kristin | NA |
| Blank | Stephanie | Grant relationship with merck; Grant relationship with Acrivon; Grant relationship with Mersana; Grant relationship with GSK; Grant relationship with Aravive; Grant relationship with Astra Zeneca; Grant relationship with Zentalis; Grant relationship with Seattle Genetics |
| Boyd | Leslie | Astra Zeneca:Consultant |
| Brown | Jubilee | NA |
| Carey | Mark | Stockholder/Shareholder - privately held relationship with aiGene; Speakers' Bureau(s) relationship with AbbVie; Speakers' Bureau(s) relationship with Verastem Oncology; Stockholder/Shareholder relationship with Zymeworks; Stockholder/Shareholder - privately held relationship with Hexamer Therapeutics; Consulting relationship with Hexamer Therapeutics; Stockholder/Shareholder - publicly traded relationship with Bioatla; Stockholder/Shareholder - publicly traded relationship with Bausch Health Companies; Stockholder/Shareholder - privately held relationship with Dental Today |
| Chappell | Nicole | NA |
| Chase | Dana | Honoraria relationship with Seagen/Genmab; Honoraria relationship with Immunogen; Consulting relationship with AstraZeneca; Consulting relationship with GSK; Consulting relationship with AstraZeneca; Honoraria relationship with GSK; Honoraria relationship with AstraZeneca; Honoraria relationship with Seagen/Genmab; Honoraria relationship with Immunogen; Consulting relationship with GSK; Honoraria relationship with AstraZeneca; Honoraria relationship with GSK |
| Cloven | Noelle | advisory board relationship with Immunogen; advisory board relationship with Profound; advisory board relationship with Zentalis; advisory board relationship with Kartos; advisory board relationship with GSK; advisory board relationship with astra zeneca |
| Coleman | Robert | IDMC relationship with BMS; Grant relationship with Pharma&; Consulting relationship with GSK; IDMC relationship with eisai; Grant relationship with Genentech/Roche; Consulting relationship with DSI; Consulting relationship with BioNtech; Consulting relationship with Seagen/Pfizer; Consulting relationship with astrazeneca; Consulting relationship with merck; Consulting relationship with immunogen; IDMC relationship with BMS; Grant relationship with Karyopharm; Consulting relationship with verastem; Employee/Founding Member relationship with Vaniam Group; Board Membership relationship with GOG Foundation; Grant relationship with abbvie/immunogen; Consulting relationship with gilead; Consulting relationship with DSI; Consulting relationship with mersana; Consulting relationship with GSK; Consulting relationship with alkermes; Grant relationship with |

| | | |
|------------|------------|---|
| | | seagen/genmab; Consulting relationship with Merck; Consulting relationship with astrazeneca; Consulting relationship with genmab/Profoundbio; Grant relationship with abbvie; Consulting relationship with Immunogen |
| Corr | Bradley | Funded research relationship with Immunogen; Advisory Board relationship with Merck; Institutional; Advisory Board relationship with Immunogen; Advisory Board relationship with GSK; Institutional; Advisory board relationship with Astrazeneca; Institutional; Speakers' Bureau(s) relationship with Tempus; Speakers' Bureau(s) relationship with Top Line Bio; Advisory Board relationship with Eisai; Speakers' Bureau(s) relationship with Targeted Oncology; Advisory Board relationship with Gilead |
| Crafton | Sarah | NA |
| Dilley | Sarah | Intuitive :Consultant |
| Drew | Yvette | Speakers' Bureau(s) relationship with Merck; Speakers' Bureau(s) relationship with AstraZeneca; Speakers' Bureau(s) relationship with AbbVie; Speakers' Bureau(s) relationship with Glaxosmithkline |
| Einstein | M. Heather | NA |
| Erickson | Britt | Consulting relationship with Merck; Consulting relationship with Gilead; Consulting relationship with GSK; Consulting relationship with AstraZeneca; Consulting relationship with AbbVie |
| Esselen | Kate | NA |
| Gien | Lilian | Consulting relationship with Astra Zeneca; Consulting relationship with Abbvie; Speaker's honoraria relationship with GSK; Speaker's honoraria relationship with Merck |
| Grisham | Rachel | Consulting relationship with Verastem; Consulting relationship with AZ; Consulting relationship with Signatera; Consulting relationship with Myriad; Consulting relationship with Springworks; Consulting relationship with Aptitude Health; Consulting relationship with GSK; Consulting relationship with GOG Foundation; Consulting relationship with Corcept |
| Hardesty | Melissa | AstraZeneca-Merck:Consultant,GSK, Sankyo, Eisai:Consultant,Merck:Speakers Bureau |
| Hays | John | Consulting relationship with AstraZeneca; Personal; Consulting relationship with Mersana; Personal; Grant relationship with Beigene; Institutional; Grant relationship with Eisai; Institutional; Grant relationship with EMD Serono; Institutional; Consulting relationship with Pfizer; Personal; Consulting relationship with Mural Oncology |
| Herzog | Thomas | Consulting relationship with Merck; Consulting relationship with Genmab; Consulting relationship with Abbvie; Consulting relationship with Aadi; Consulting relationship with AZ; Consulting relationship with Caris; Consulting relationship with Clovis; Consulting relationship with Epsilon; Consulting relationship with Genentech; Consulting relationship with GSK; Consulting relationship with Eisai; Consulting relationship with Mersana; Consulting relationship with Corcept; Consulting relationship with Pfizer |
| Hillman | Robert | Grant relationship with Sumitomo Pharma |
| Hopp | Libby | Advisory Board relationship with Immunogen |
| Huang | Marilyn | AZ, Natera, Immunogen, Pfizer, Seagen, GSK, Merck:Scientific/Medical Advisory Board Member,Merck:Research Grant Overall Principal Investigator |
| Huffman | Laura | NA |
| Hutchcraft | Megan | NA |
| Irish | Sarah | NA |
| Kim | Rachel | NA |
| Knisely | Anne | NA |
| Kopelman | Zachary | NA |
| Krivak | Thomas | GSK:Consultant,GSK:Speakers Bureau,Myriad:Consultant,Myriad:Speakers Bureau,Astrazeneca:Speakers Bureau,Seagen:Speakers Bureau,Merck:Speakers Bureau |
| Kuhn | Theresa | NA |
| Levytska | Khrystyna | NA |
| Lheureux | Stephanie | Grant relationship with Astra-Zeneca; Consulting relationship with Seagen; Consulting relationship with Eisai; Consulting relationship with merck; Grant relationship with Roche; Consulting relationship with GSK; Consulting relationship with astra zeneca; Grant relationship with GSK; Consulting relationship with Roche |
| Lin | Ken | Stockholder/Shareholder relationship with Novo Nordisk |
| MacDonald | Jennifer | Glasko Smith Kline:Speakers Bureau,Mersana:Scientific/Medical Advisory Board Member |
| Marcus | Jenna | GSK:Speakers Bureau,Pfizer:Speakers Bureau,Intuitive:Consultant |
| McAlpine | Jessica | Speakers' Bureau(s) relationship with GSK; Speakers' Bureau(s) relationship with Astra Zeneca |
| McHale | Michael | Consulting relationship with eisai |
| Meyer | Larissa | Bristol Myers Squibb:Stock Shareholder,Invitae:Stock Shareholder,Johnson & Johnson:Stock Shareholder,Denali:Stock Shareholder,Crispr Therapeutics:Stock Shareholder,AstraZeneca:Research Grant Overall Principal Investigator,Bristol Myers Squibb:Consultant,Merck:Research Grant Overall Principal Investigator, Stockholder/Shareholder relationship with Denali; Stockholder/Shareholder relationship with Johnson and Johnson; Stockholder/Shareholder relationship with Bristol Myer Squibb; Stockholder/Shareholder relationship with Crispr |
| Michener | Chad | Seattle Genetics:Research Grant Site Principal Investigator,Frantz Medical:Research Grant Site Principal Investigator,MedaSync:Stock Shareholder,Merck:Research Grant Site Principal Investigator,Novella:Research Grant Site Principal Investigator,AstraZeneca:Research Grant Site Principal Investigator |

| | | |
|-----------------------|-----------|---|
| Moore | Kathleen | Consulting relationship with duality, daiichi sankyo, eisai, gsk, genentech/roche,; advisory boards relationship with astra zeneca, aadi, aravive, alkemeres, blueprint, caris,; Consulting relationship with verastem, vbl therapeutics, zentalis; Consulting relationship with myriad, novarits, oncxerna, onconova, pannavance, regeneron; Consulting relationship with immunogen, imab, janssen, lilly, mereo, merck, mersana, |
| Moroney | Marisa | NA |
| Nasioudis | Dimitrios | NA |
| Nauman | Robert W | Merck:Consultant,Tesaro/GSK:Consultant,AstraZeneca:Consultant,Immunogen:Consultant,SutroBio:Consultant,Ei sai:Consultant,Agenus:Consultant,Seagen:Speakers Bureau,BMS:Research Grant Overall Principal Investigator,Mersana:Research Grant Site Principal Investigator,SutroBio:Research Grant Overall Principal Investigator,Amgen:Public Stock Shareholder, Clovis:Consultant |
| Neff | Robert | Steering committee relationship with Aadi Biosciences; Consulting relationship with AstraZeneca |
| Nickles | Fader | Symposium speaker relationship with Gynecologic Oncology Group Foundation; Advisory Board relationship with GSK |
| Pham | Melissa | NA |
| Powell | Matthew | Consulting relationship with AstraZeneca Pharma; Research support relationship with GlaxoSmithKline; Consulting relationship with Merck Sharp & Dohme; Consulting relationship with Aadi Bioscience |
| Richardson | Debra | Consulting relationship with Immunogen; Consulting relationship with ProfoundBio; Consulting relationship with Eisai; clinical trial relationship with Shattuck Labs; Consulting relationship with Daiichi Sankyo; Grant relationship with GlaxoSmithKline; research support relationship with Mersana; clinical trial relationship with AstraZeneca; clinical trial relationship with Profound Bio; clinical trial relationship with Immunogen; clinical trial relationship with Karyopharm; clinical trial relationship with Lilly; Consulting relationship with AstraZeneca; Consulting relationship with Mersana; clinical trial relationship with Aadi; clinical trial relationship with Valerio Therapeutics; clinical trial relationship with OnCusp Therapeutics; clinical trial relationship with A2A pharmaceuticals; clinical trial relationship with Allorian; clinical trial relationship with Blueprint Medicines; clinical trial relationship with DualityBio; clinical trial relationship with Nimbus Therapeutics; clinical trial relationship with Nurix Therapeutics; clinical trial relationship with PMV pharmaceuticals; clinical trial relationship with Acrivon; clinical trial relationship with CanarioBio; clinical trial relationship with Hookipa; clinical trial relationship with Celsion; Consulting relationship with GlaxoSmithKline |
| Robison | Katina | NA |
| Rutledge | Teresa | NA |
| Salani | Ritu | Elsevier:Consultant,GSK:Scientific/Medical Advisory Board Member,Merck:Scientific/Medical Advisory Board Member,Seagen/Pfizer:Scientific/Medical Advisory Board Member,Karyopharm:Scientific/Medical Advisory Board Member,Regeneron:Scientific/Medical Advisory Board Member,UpToDate:Consultant |
| Sandstrom | Tracy | NA |
| Shafer | Aaron | NA |
| Soliman | Pamela | GSK, MERCK, Novartis,Leap Therapeutics:Research Grant Overall Principal Investigator,GSK, Aadi:Scientific/Medical Advisory Board Member,Medscape:Consultant |
| Teoh | Deanna | Single ad board participation relationship with Asieris; Research support relationship with Jounce Therapeutics; Research support relationship with Moderna; Research support relationship with GSK |
| TestUser | Jennifer | Board Membership relationship with Test |
| Veljovich | Dan | Stockholder/Shareholder relationship with Adaptive Biotechnology; Speakers' Bureau(s) relationship with GSK; Consulting relationship with Merck; Consulting relationship with Eisai; Consulting relationship with Abbvie; Stockholder/Shareholder relationship with Abbott Laboratories; Stockholder/Shareholder relationship with ABBVIE; Stockholder/Shareholder relationship with Intuitive Surgical; Stockholder/Shareholder relationship with AstraZeneca; Stockholder/Shareholder relationship with BioNTech; Stockholder/Shareholder relationship with Bristol Meyers Squibb; Stockholder/Shareholder relationship with Gilead; Stockholder/Shareholder relationship with GSK; Stockholder/Shareholder relationship with Haleon PLC; Speakers' Bureau(s) relationship with Pfizer; Stockholder/Shareholder relationship with Johnson & Johnson; Stockholder/Shareholder relationship with Medtronic; Stockholder/Shareholder relationship with Merck & Co.; Stockholder/Shareholder relationship with Moderna; Stockholder/Shareholder relationship with Pfizer; Stockholder/Shareholder relationship with TelaDoc; Consulting relationship with AstraZeneca; Stockholder/Shareholder relationship with United Health; Stockholder/Shareholder relationship with Veeva Systems; Stockholder/Shareholder relationship with Zimmer Biomet; Stockholder/Shareholder relationship with CVS Health; Stockholder/Shareholder relationship with Elevance Health; Stockholder/Shareholder relationship with Doximity; Stockholder/Shareholder relationship with Crisper Therapeutics |
| Venkat | Puja | NA |
| Vicus | Danielle | Advisory board relationship with GSK; Consulting relationship with Integra; Consulting relationship with Knight |
| Vranes | Chelsey | NA |
| Wahner Hendrickson | Andrea | Prolynx:Other,TORL:Other,Oxcia:Scientific/Medical Advisory Board Member |

| | | |
|------------|---------|---|
| Willmott | Lyndsay | Speakers' Bureau(s) relationship with Astra Zeneca; Advisory board relationship with OncoC4; Speakers' Bureau(s) relationship with Eisai; Speakers' Bureau(s) relationship with Seagen/Pfizer; Speakers' Bureau(s) relationship with Merck; Advisory board relationship with Merck; Speakers' Bureau(s) relationship with Immunogen |
| Winkler | Stuart | NA |
| Winterhoff | Boris J | Verastem:Stock Shareholder,Exact Sciences:Stock Shareholder |